Close

Have A Question?


Connect with Camargo today.

Contact Us

The Camargo Blog

Get insight and information from our team of experts to improve your pharmaceutical development and commercialization strategy.


January 2nd, 2013

2012 505(b)(2) Approvals—Record Year

December 16th, 2012

Suit to Challenge Use of REMS to Block Generics and 505(b)(2)

September 26th, 2012

Orphan Designation without Exclusivity: Court Asked to Decide

September 25th, 2012

New Generic Stability Requirements

August 8th, 2012

K-V Pharma Bankrupt—Claims FDA Doesn’t Back Makena

June 18th, 2012

REMS in Congress

April 19th, 2012

ViroPharma Denied Request for 3-year Exclusivity

April 15th, 2012

Drug Development Planned Like the Titanic

April 12th, 2012

NIH Head Urges Repositioning/Repurposing

December 21st, 2011

What is an Approved DESI Product?

October 3rd, 2011

Don’t Launch Unapproved Products After 9/19/2011

September 11th, 2011

AB Rated 505(b)(2)’s

August 7th, 2011

2012 PDUFA User Fees

June 24th, 2011

Whew! Supreme Court Rules Generic Labels Must Track RLD

June 14th, 2011

K-V’s Makena Part 4: Statistical versus Clinical Significance

June 9th, 2011

Patent Cliff Causes Pfizer Cuts

June 8th, 2011

Role of In Vitro / In Vivo Metabolism Studies in 505(b)(2) Drug Development of Metabolite Products

June 2nd, 2011

Ophthalmics: 21 CFR 314 94(a)(9)(iv) No Longer Applies

June 2nd, 2011

Why Generic Companies Might Like 505(b)(2)

May 31st, 2011

K-V’s Makena: Part 3: Use of Public Information for 505(b)(2) Approvals

May 23rd, 2011

K-V’s Makena Part 2: Accelerated Approval Subpart H

May 18th, 2011

K-V’s Makena® Part 1: 505(b)(1) or 505(b)2)?

May 16th, 2011

K-V’s Makena®: A trove of 505(b)(2) Lessons

March 23rd, 2011

Revised Safety Reporting for BE/BA Studies Effective March 28, 2011

March 10th, 2011

User Fee Waivers: What is an Affiliate? New Guidance Issued

February 21st, 2011

Approvals of ANDAs Slows

February 7th, 2011

Mitosol—An Orphan & 505(b)(2) without clinical studies

February 1st, 2011

Injectables: 505j or 505(b)(2)?

January 19th, 2011

REMS for 505(b)(2) Products?

January 6th, 2011

2010 505(b)(2) Approvals

December 20th, 2010

PDUFA Fee Waiver: Plan Ahead

December 13th, 2010

Use of Pharmacokinetic n(PK) Modeling & Steady-State Simulations in 505(b)(2) Drug Development

December 11th, 2010

Nuedexta®—Smart Pharmacology to Treat a Unique Disorder

November 22nd, 2010

Endpoint for GI Toxicity Clarified

October 18th, 2010

Company Officials Personally Liable

October 15th, 2010

When is an IND Required?

October 6th, 2010

505(b)(2)s with Minimal Sponsor Studies

October 5th, 2010

Why have a Quality Overall Summary for the Quality Module?

August 31st, 2010

Failed 505(b)(2)?: Vivus™ Qnexa

August 23rd, 2010

Lannett’s Morphine Sulfate Oral Solution: 505(b)(2) or 505j?

August 23rd, 2010

Will We Have Generic User Fees? Public Meeting to Be Held.

August 20th, 2010

Generic Lovenox: 505j or 505(b)(2)

Page 5 of 9


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights